41389-15-5

Upstream product

• 41388-50-5 1-(allyloxy)-3-bromobenzene 
• 591-20-8 3-Bromophenol 

Downstream Products

• 13849-32-6 3,4-dihydro-5-hydroxy-2H-1-benzopyran 
• 319478-14-3 5-bromochromane 
• 312608-50-7 (+/-)-4-bromo-2-hydroxymethyl-2,3-dihydrobenzofuran 

Relevant academic research and scientific papers

Imidazo ring PAR4 antagonist and medical applications thereof

The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.

ARYLPIPERAZINES

The present invention relates to arylpiperazines, and to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in Parkinson patients,

TRPV1 ANTAGONISTS

Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using

Synthesis and affninity evaluation for AT1 receptor of phenylsalicylaldoxime-derivatives structurally related to sartans

In this work we reported thy synthesis of new potential AT1 antagonists through the replacement of the biphenyltetrazole portion of the losartan with biphenylaldoximic (2) and phenylsalicylaldoximic (3a) moieties. Moreover, also the trifluoromethylpyrazol

Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor β

Salicylaldoximes possess a hydrogen-bonded pseudocyclic A′ ring in place of the typical phenolic A ring that is characteristic of most estrogen receptor (ER) ligands. Monoaryl-substituted salicylaldoximes were obtained by replacing the phenol moiety (ring

1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE

The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.]

The thermal [3, 3] claisen rearrangement of the 3-substituted phenyl allyl and propargyl ethers. The synthesis of 4-halobenzo[b]furans

The thermal [3, 3] Claisen rearrangement of the 3-substituted phenyl allyl and propargyl ethers is regioselective. The major product of the reaction incorporates a 1, 2, 3-trisubstituted benzene ring. The 2-allenylphenol intermediates can be manipulated i

RING-SUBSTITUTED 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENES AND 3-AMINOCHROMANES

The present invention provides novel ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes which exhibit binding activity at the serotonin 1A receptor.

METHOD OF INHIBITING GASTRIC ACID SECRETION WITH BENZODIOXANES

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.

METHOD OF INHIBITING GASTRIC ACID SECRETION

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.